Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PHRM 844 Module #2 > Anti-Hyperlipidemic Drugs > Flashcards

Anti-Hyperlipidemic Drugs Flashcards

1
Q

Major lipids

A

cholesterol: essential component of cell membranes; precursor to sterols and steroids
triglyceride: storage form of fuel to support generation of high energy compounds; component of structural lipids
both are transported in blood in macromolecular aggregates known as lipoproteins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Know the relative size, composition, and physiological function of the major classes of lipoproteins

A

lipids form lipoproteins to help them move around the body
lipoproteins transport cholesterol & triglycerides in blood; spherical particles with phospholipid, free cholesterol & protein making up surface; core made up of triglyceride & cholesterol ester; apoproteins on surface are critical in regulating transport & metabolism; lipoprotein lipase system releases free FAs from lipoproteins
major classes of lipoproteins: chylomicrons, VLDL, IDL, LDL, HDL
classes based on density, composition, and electrophoretic mobility

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Chylomicrons

A

involved in transport of dietary lipids from gut to liver and adipose tissue
dumped into lymphatic system and makes its way through the body

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

VLDL - very low density lipoprotein

A

secreted by liver into blood as a source of triglycerides

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

IDL - intermediate density lipoprotein

A

triglyceride-depleted VLDLs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

LDL - low density lipoprotein

A

main cholesterol form in blood

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

HDL - high density lipoprotein

A

secreted by liver and acquire cholesterol from peripheral tissue and atheromas (reverse cholesterol transport)
bring cholesterol from peripheral tissues and back into liver

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Lipoproteins sizes

A

bigger they are –> less dense they are
biggest: chylomicron –> VLDL –> LDL –> HDL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Lipoproteins compositions

A

chylomicrons: mostly triglycerides
VLDL: mostly triglycerides, more cholesterol too
LDL: more cholesterol relative to TGs
HDL: mostly protein

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Important apolipoproteins

A

ApoA-I
ApoB-100
ApoB-48
ApoE
ApoCII

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

ApoA-I

A

structural in HDL; ligand of ABCA1 receptor mediates reverse cholesterol transport produced in liver and intestine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

ApoB-100

A

structural in VLDL, IDL, LDL; LDL receptor ligand produced in liver

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

ApoB-48

A

structural in chylomicrons produced in intestine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

ApoE

A

ligand for LDL remnant receptor reverse cholesterol transport with HDL; produced in liver and other tissues; helps get cholesterol back into the liver

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

ApoCII

A

found in chylomicrons, VLDL; binds to lipoprotein lipase to enhance TG hydrolysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Know the exogenous and endogenous pathways for lipid absorption and transport

A

LDL-lipoprotein lipase: in capillaries of fat, cardiac & skeletal muscle
HL-hepatic lipase: produced in liver, key in converting IDL to LDL
CETP-cholesterol ester transfer protain: more cholesterol esters from HDLs into IDLs in exchange for trigylcerides

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Endogenous pathway

A

liver secretes VLDL –> IDL –> LDL –> cholesterol distributed throughout the body

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Exogenous pathway

A

dietary fat + cholesterol –> intestine –> chylomicrons –> chylomicron remnants –> liver

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Know the role of the LDL receptor in lipid metabolism, and factors that regulate LDL receptor levels

A

LDL goes in through LDL receptors –> lipoproteins taken into lysosome
mLDL goes in through CD36 or SR-A –> lipoproteins taken into lysosome
fate 1: cholesterol is esterified, now have long chain FA (storage form)
fate 2: free cholesterol effluxed, HDL stimulates this
CEH = cholesterol ester hydrolase, hydrolyzes cholesterol ester back to free cholesterol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Understand the central role of the liver in cholesterol synthesis and lipid distribution

A

De novo synthesis is the major source of cholesterol
liver synthesis is most critical to total body burden
mevalonate is the key building block for cholesterol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Lipoprotein disorders

A

detected by measuring lipid in serum after a 10 hr fast
ratio of total cholesterol to HDL-cholesterol is key in assessing risk of CVD
ratio > 4.5 is associated with increased risk of CVD
ratio of </= 3.5 is desirable, ratio of < 3 is optimal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Give the diseases that are associated with hyperlipoproteinemia and hypertryglyceridemia

A

hyperlipoproteinemia: atherosclerosis - excess accumulation of cholesterol in vascular smooth muscle, premature coronary artery disease, neurologic disease - stroke
hypertriglyceridemia: pancreatitis, xanthomas, increased risk of CHD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Atherosclerosis

A

fatty streak - initial stage, leads to accumulated plaques, reduces blood flow
LDL receptors are present on endothelial cells
monocyte squeezes in b/w endothelium, gets into intima –> oxidized (modified) LDL gets into initma and stimulates T cell sectretion –> T cells secrease # of pro-inflammatory cytokines with chemotactic effect on monocytes –> causes differentiation of monocytes into macrophages –> macrophage starts to take up LDL –> store as cholesterol esters –> forms foam cells –> cell dies

24
Q

Know the strategies for controlling hyperlipidemias and give the molecular targets, mechanism of action, and major side-effects for: statins, bile acid sequestrants, ezetimibe, bempedoic acid fibrates, niacin, omega-3 fatty acids

A

goals of therapy: prevent formation of atherosclerotic plaques; decrease reabsorption of excreted bile acid; decrease secretion of VLDL from liver; decrease synthesis of cholesterol; increase hydrolysis of lipoprotein triglycerides
each 10% reduction in cholesterol levels is associated with 10-30% reduction in incidence of coronary heart disease

25
Q

Drugs mainly for high cholesterol

A

bile acid binding resins
inhibitors of cholesterol absorption
inhibitors of cholesterol synthesis
PCSK9 inhibitors
MTTP inhibitors

26
Q

Drugs mainly for high triglycerides

A

fibrates
niacin
omega-3 fatty acids

27
Q

Strategies for controlling hyperlipidemia

A

statins - inhibit HMG CoA reductase
fibrates, niacin, omega-3 FAs - lipoprotein catabolism
bile acid sequestrants - inhibit reabsorption of cholesterol
ezetimibe - inhibits diet cholesterol

28
Q

Bile acid-binding resins

A

MOA: inhibits reabsorption of bile acids from intestine by binding bile acids to form insoluble complex excreted in feces; exchanging bile acid for chloride; want to interfere with the recycling and make the liver use more cholesterol to make bile acids, get more cholesterol, bring LDLs back into liver and prevent going into peripheral tissues
up-regulate LDL receptors in liver when liver’s running low on cholesterol
ex: cholestyramine and colestipol - polymers with (+) charge, exchange counterion chloride) for bile acids
cholesterol oxidized by CYP450s to cholic acid - negatively charges, will bind to the (+) charged resins

29
Q

Bile acid binding resins SEs

A

constipation and bloating

30
Q

Bile acid binding resins drug interactions

A

acetaminophen, thiazides, warfarin, digoxin, fibrates, ezetimibe, oral contraceptive, corticosteroids, thiazolidinediones

31
Q

Ezetimibe

A

cholesterol absorption inhibitor; inhibits intestinal absorption of phyosterols and cholesterol
MOA: inhibits intestinal absorption of cholesterol from dietary sources and reabsorption of cholesterol excreted in bile (inhibits NPC1L1 - Neimann-Pick C1-like 1, ezetimibe binds to this transporter)

32
Q

NPC1L1 - cholesterol transporter

A

expressed on apical surface of enterocytes in small intestine
cholesterol activates sterile sensing domain (SSD) which stimulates endocytosis, brings in cholesterol that’s bound in the membrane around the transporter
ezetimibe blocks this transporter

33
Q

Ezetimibe SEs

A

low incidence of liver/skeletal muscle damage

34
Q

Recognize the molecular structure of statins and indicate which statins are prodrugs

A

HMG-CoA reductase inhibitors - “statins” statins are derivatives of mevalonic acid
lovastatin and simvastatin are prodrugs

35
Q

HMG-CoA reductase inhibitors

A

MOA: competitively inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis
up-regulate LDL receptors enabling more LDL delivered to liver, thus reducing plasma cholesterol
prevent conversion of HMG-CoA to mevalonic acid

36
Q

Mechanism for upregulation of hepatic LDL receptors by statins

A

reducing synthesis of cholesterol in the liver, causes the liver to react, allows it to take more LDL up from plasma
SREBP - sterol regulatory element binding protein has 2 domains - regulatory and basic helix loop helix domain; this complex stays when sterols are present; SCAP - SREBP cleavage activating protein keeps it in the ER when a lot of sterols are around
when sterols depleted by inhibiting HMG-CoA reductase –> site one protease (S1P) cleaves SREBP, site two protease cleaves bHLH from transmembrane domain –> complex translates to golgi apparatus –> goes to nucleus to activate transcription –> transcription + production of LDLr –> incrase hepatic LDL uptake

37
Q

HMG-CoA reductase inhibitors metabolism

A

CYP3A4: lovastatin, simvastatin and atorvastatin - tend to accumulate in presence of drugs that inhibit or compete for CYP 3A4: macrolide antibiotics, cyclosporine, ketoconazole, grapefruit juice
CYP 2C9: fluvastatin, rosuvastatin - inhibitors may increase plasma levels: cimetidine, metronidazole, amiodarone
sulfation: pravastatin, most excreted unchanged
pitavastatin excreted unchanged in bile, undergoes enterohepatic recirculation

38
Q

HMG-CoA reductase inhibitors SEs

A

skeletal muscle effects: rhabdomyolysis with renal dysfunction secondary to myoglobinuria, monitor creatine phosphokinase; increased incidence when co-adm with CYP inhibitors, gemfibrozil
hepatotoxicity - monitor serum transaminase activity
increased incidence of T2DM

39
Q

ATP-citrate lyase inhibitor

A

bempedoic acid (nexletol)
adjunct to statins
inhibits OAT2 in renal tubules - inhibits secretion of uric acid

40
Q

Bempedoic acid SEs

A

hyperuricemia and gout

41
Q

Drugs used to lower serum cholesterol in pts with homozygous familial hypercholesterolemia

A

LDL-r function is severely reduced in this condition
lomitapide
mipomersen
angiopoietin-like protein 3

42
Q

Recognize the molecular structure of fibrates and indicate which fibrate is a prodrug

A

fibric acid derivatives: peroxisome proliferator-activated receptor-alpha activators (PPARalpha)
fenofibrate must undergo bioactivation to fenofibric acid
gemfibrozil

43
Q

Fibrates

A

bind to PPAR-alpha and regulate gene transcription along with the retinoic acid receptor (RXR) to reduce triglyceride levels

44
Q

Fibrates SEs

A

gallstones (cholelithiasis)
skeletal muscle effects - rhabdomyolysis
drug interaction: potentiate the effects of warfarin

45
Q

Niacin MOA

A

reduces serum triglycerides
blocks the mobilization of FFAs from adipose tissue, so less FFAs are taken to the liverm less TG synthesis, less VLDL export, decrease LDL, increase HDL
increases lipase activity to increase clearance of VLDL –> decreases hepatic VLDL production –> may significantly reduce serum LDL and TG –> increases HDL levels

niacin inhibits a hormone-sensitive lipase in adipose tissue which reduces the breakdown of triglycerides to free fatty acids, and the transport of free fatty acids to the liver.
the reduction in transport of free fatty acids from fat to liver decreases hepatic triglyceride synthesis
the reduction in hepatic triglyceride synthesis inhibits VLDL secretion from hepatocytes, which in turn decreases the production of LDL.

46
Q

Niacin targets

A

adipose tissue: inhibits TG lipolysis by hormone-sensitive lipase - decreasing FA transport to liver via activation of GPR109A
liver: inhibits FA synthesis and esterification reducing TG export via VLDL - reduces clearance of ApoA-I but not CEs, increasing HDL levels and reverse transport
macrophages: increases expression of CD36 and ABCA1, decreasing CE content via HDL-mediated reverse transport

47
Q

Niacin SEs

A

marked vasodilation (flushing), itching, tingling of upper body and headache - prostaglandins mediate these, treat with aspirin or ibuprofen
hepatotoxicity

48
Q

Omega-3 fatty acid ethyl esters

A

nutrients
combo of ethyl esters of omega-3 fatty acids
lovaza, omtryg, vascepa
MOA: reduce serum triglycerides; reduce synthesis of triglyceride in liver: omega-3 FAs are poor substrates for enzymes responsible for TG synthesis; inhibit esterification of other FAs

49
Q

Omega-3 FAs SEs

A

can increase LDLc levels, not EPA-ethyl ester alone
combined with statins to reduce LDLc level

50
Q

Eicosapentaenoic acid (an omega-3 FA)

A

TXA3- less potent in stimulating platelet aggregation than TXA2; PGI3 - equipotent in ihibiting platelet aggregation than PGI2
low incidence of atherosclerotic disease with a tendency to bleed
inhibiting platelet aggregation that would normally be mediated by TXA2, still maintaining good prostacyclin activity even if you incorporate this FA into the synthetic pathway

51
Q

Explain the mechanism of action of angiopoietin-like protein 3 inhibitors

A

reduce LDL levels independently of LDLrs - mechanism does not require LDL-R
evinacumab (evkeeza): monoclonal antibody
increases lipoprotein lipase and endothelial lipase activity by preventing ANGPTL3 mediated inhibition, this binding interferes with the ANGPTL3 ability to inhibit activity of LPL and EL; lowers LDLc
evinacumab allows greater breakdown by LPL and EL, by allowing greater breakdown of TGs by these lipases from the VLDL, the IDL that results is more likely to be cleared by the remnant receptor as an IDL than to be processed to an LDL (reduce conversion of IDL to LDL)

52
Q

Explain the mechanism of action of mipomerson and lomitapide, and their primary toxicities

A

lomitapide and mipomerson - inhibits apo B lipoprotein synthesis

53
Q

Lomitapide

A

juxtapid
small molecule microsomal TG transfer protein (MTTP) inhibitor
inhibits assembly of Apo B containing lipoproteins in liver + intestine - interferes with assembly of both VLDL and chylomicrons
high risk of liver damage

54
Q

Lomitapide MOA

A

mechanism does not require LDL-R
MTTP inhibitors inhibit VLDL assembly and reduce VLDL secretion into bloodstream from liver
small molecule inhibits microsomal triglyceride transport protein (MTTP); also works in the intestines - interferes with packaging of chylomicrons affect ability to absorb lipophilic compounds

55
Q

Mipomersen

A

kynamro
phosphorothioate anti-sense oligonucleotide inhibitor of Apo B100, more specific to ApoB100, greater effect on VLDL export
hybridizes Apo B100 mRNA in liver and promotes degradation
binds to Apo B100 mRNA and causes it to be destroyed; duplex mRNA w/ oligo, mRNA will be degraded –> degrading Apo B100 mRNA reduces Apo B100 protein, reduce VLDL export
VLDL are processed LDL, so reducing VLDL export will reduce these serum LDL cholesterol as well
phosphorothioate has an added sulfur instead of oxygen, decreases ability of nucleases to degrade this oligo
high risk of liver damage

56
Q

Explain the mechanism of action of the PCSK9 inhibitors

A

augment the clearance of LDL cholesterol
PCSK9 - proprotein convertase subtilisin kexin type 9 (serine protease) - promotes degradation of LDL receptors in liver
MOA: controls level of LDLr on surface of hepatocytes –> binds to LDLr and marks it for internalization + degradation; develop antibody against PCSK9 that will bind this soluble enzyme, prevent it from binding LDLr allowing recycling of receptor when internalized
alirocumab and evolocumab are human IgG Abs against PCSK9 - increase LDLr # and reduce serum LDLc levels
inclisiran: siRNA hybridizes PCSK9 mRNA and directs degradation of PCSK9 mRNA in hepatocytes, lowers LDLc

57
Q

PCSK9 inhibitors SEs

A

injection site rxn
arthralgia

PHRM 844 Module #2 (23 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions